MAGEC2 and head and neck cancer: In other tumors, MAGE-C2/CT10 protein was previously identified in 34%-48% of hepatocellular carcinomas [20],[48], in 43% of multiple myeloma [49], in 20% of high-grade urothelial carcinomas of the urinary bladder [18], in 20% of head and neck cancers [28], and in 43% of melanomas, respectively.